Cargando…
Quantitative Characterization of Olaparib in Nanodelivery System and Target Cell Compartments by LC-MS/MS
Olaparib, an orally active inhibitor of poly(ADP-ribose)polymerase(PARP), is the drug of choice in the treatment of gBRCA1/2+ metastatic breast cancers. Unfortunately, Olaparib is poorly soluble with low bioavailability and tumor accumulation; nano-delivery could be a good choice to overcome these d...
Autores principales: | Ottria, Roberta, Ravelli, Alessandro, Miceli, Matteo, Casati, Sara, Orioli, Marica, Ciuffreda, Pierangela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429415/ https://www.ncbi.nlm.nih.gov/pubmed/30862103 http://dx.doi.org/10.3390/molecules24050989 |
Ejemplares similares
-
Correction: Ottria, R., et al. Quantitative Characterization of Olaparib in Nanodelivery System and Target Cell Compartments by LC-MS/MS. Molecules 2019, 24, 989
por: Ottria, Roberta, et al.
Publicado: (2019) -
Quantitative Lipidomic Analysis of Osteosarcoma Cell-Derived Products by UHPLC-MS/MS
por: Casati, Sara, et al.
Publicado: (2020) -
Urine Endocannabinoids as Novel Non-Invasive Biomarkers for Bladder Cancer at Early Stage
por: Vago, Riccardo, et al.
Publicado: (2020) -
Simple Synthesis of 17-β-O-hemisuccinate of Stanozolol for Immunoanalytical Methods
por: Casati, Silvana, et al.
Publicado: (2020) -
GC–MS analysis of soil faecal biomarkers uncovers mammalian species and the economic management of the archeological site "Le Colombare di Negrar"
por: Reggio, Chiara, et al.
Publicado: (2023)